JP6474826B2 - 化合物 - Google Patents

化合物 Download PDF

Info

Publication number
JP6474826B2
JP6474826B2 JP2016549113A JP2016549113A JP6474826B2 JP 6474826 B2 JP6474826 B2 JP 6474826B2 JP 2016549113 A JP2016549113 A JP 2016549113A JP 2016549113 A JP2016549113 A JP 2016549113A JP 6474826 B2 JP6474826 B2 JP 6474826B2
Authority
JP
Japan
Prior art keywords
amino
pyrrolo
ethoxy
methanone
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016549113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017504635A5 (enExample
JP2017504635A (ja
Inventor
ディン、シャオ
リウ、キアン
ロン、カイ
サン、インシャ
ルイジ、ピエロ、スタシ
ワン、ゼホン
シュ、キオンフェン
コリン、マイケル、エッジ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2017504635A publication Critical patent/JP2017504635A/ja
Publication of JP2017504635A5 publication Critical patent/JP2017504635A5/ja
Application granted granted Critical
Publication of JP6474826B2 publication Critical patent/JP6474826B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2016549113A 2014-01-29 2015-01-28 化合物 Expired - Fee Related JP6474826B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/000140 2014-01-29
CN2014000140 2014-01-29
PCT/CN2015/000054 WO2015113451A1 (en) 2014-01-29 2015-01-28 Compounds

Publications (3)

Publication Number Publication Date
JP2017504635A JP2017504635A (ja) 2017-02-09
JP2017504635A5 JP2017504635A5 (enExample) 2018-03-08
JP6474826B2 true JP6474826B2 (ja) 2019-02-27

Family

ID=53756223

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016549113A Expired - Fee Related JP6474826B2 (ja) 2014-01-29 2015-01-28 化合物

Country Status (9)

Country Link
US (1) US9815841B2 (enExample)
EP (1) EP3099694B1 (enExample)
JP (1) JP6474826B2 (enExample)
CN (1) CN105980388B (enExample)
AU (2) AU2015210554A1 (enExample)
CA (1) CA2937430A1 (enExample)
ES (1) ES2717757T3 (enExample)
RU (1) RU2016134751A (enExample)
WO (1) WO2015113451A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20161443A1 (es) 2014-01-29 2017-01-06 Glaxosmithkline Ip Dev Ltd Compuestos
EP3778605A3 (en) * 2015-02-13 2021-03-10 Dana Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same
JP2018537502A (ja) 2015-12-16 2018-12-20 サウザーン リサーチ インスチチュート ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法
CA3049820A1 (en) 2017-01-25 2018-08-02 Glaxosmithkline Intellectual Property Development Limited Compounds for inhibiting lrrk2 kinase activity
CN110248936A (zh) * 2017-01-25 2019-09-17 葛兰素史密斯克莱知识产权发展有限公司 化合物
KR20180097162A (ko) * 2017-02-22 2018-08-30 국립암센터 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
AU2018239798B2 (en) 2017-03-23 2020-08-27 Daegu Gyeongbuk Institute Of Science And Technology Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases
CA3168211A1 (en) 2019-01-18 2020-07-23 Voronoi Co., Ltd. Pyrrolopyridine derivative and use thereof for preventing or treating protein kinase related disease
CN113614086A (zh) * 2019-01-18 2021-11-05 沃若诺伊公司 吡咯并嘧啶衍生物以及包含其作为活性成分的用于预防或治疗蛋白激酶相关的疾病的药物组合物
CZ308800B6 (cs) * 2019-02-12 2021-05-26 Univerzita Palackého v Olomouci Heterocyklické dusíkaté deriváty purinu, farmaceutické přípravky obsahující tyto deriváty a jejich použití při neuroprotekci
EP3968990A4 (en) * 2019-05-16 2023-06-07 Dana-Farber Cancer Institute, Inc. WILD-TYPE PYRROLOPYRIMIDINE INHIBITORS AND MUTANT FORMS OF LRRK2
CN111205216B (zh) * 2020-03-11 2022-03-29 连云港恒运药业有限公司 一种制备沙格列汀的方法
KR20230091150A (ko) * 2020-10-29 2023-06-22 수저우 야바오 파마슈티걸 알앤디 컴퍼니 리미티드 치환된 디아릴아민 화합물 및 이의 약학적 조성물, 제조 방법과 용도
KR20220081631A (ko) 2020-12-09 2022-06-16 보로노이 주식회사 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
WO2022155419A1 (en) * 2021-01-15 2022-07-21 ESCAPE Bio, Inc. Indazoles and azaindazoles as lrrk2 inhibitors
AU2022246081A1 (en) 2021-03-23 2023-10-12 Halia Therapeutics, Inc. Pyrimidine derivatives useful as lrrk2 kinase inhibitors
WO2023073013A1 (en) 2021-10-27 2023-05-04 H. Lundbeck A/S Lrrk2 inhibitors
CN115108991B (zh) * 2022-06-30 2023-05-05 南京理工大学 一种硝仿基吡唑起爆药及其制备方法
TW202412777A (zh) 2022-09-15 2024-04-01 丹麥商Ｈ 朗德貝克公司 富白胺酸重複激酶2（lrrk2）抑制劑

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028480A2 (en) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
WO2007042298A1 (en) * 2005-10-13 2007-04-19 Glaxo Group Limited Pyrrolopyrimidine derivatives as syk inhibitors
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009143404A1 (en) 2008-05-23 2009-11-26 Wyeth Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
BR112012006859A2 (pt) 2009-09-29 2019-09-24 Glaxo Group Ltd compostos
MX2012014158A (es) * 2010-06-04 2013-02-07 Hoffmann La Roche Derivados de aminopirimidina como moduladores de proteina cinasa rica repeticiones leucina 2 (lrrk2).
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
WO2012045195A1 (en) * 2010-10-09 2012-04-12 Abbott Laboratories Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases
CN103298474B (zh) 2010-11-10 2016-06-29 无限药品股份有限公司 杂环化合物及其用途
PH12013500880A1 (en) 2010-11-10 2013-07-01 Hoffmann La Roche Pyrazole aminopyrimidine derivatives as lrrk2 modulators
JP5937102B2 (ja) 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
CA2831634C (en) * 2011-04-21 2019-11-12 Origenis Gmbh Pyrazolo [4,3-d] pyrimidines useful as kinase inhibitors
AU2012311184A1 (en) 2011-09-22 2014-03-06 Pfizer Inc. Pyrrolopyrimidine and purine derivatives
BR112014012822A8 (pt) 2011-11-30 2017-07-11 Hoffmann La Roche Radioligantes rotulados com flúor-18 e carbono-11 para imagiologia por tomografia por emissão de pósitrons (pet) para lrrk2
GB201204985D0 (en) * 2012-03-21 2012-05-02 Genentech Inc Compounds
JP6218808B2 (ja) 2012-05-03 2017-10-25 ジェネンテック， インコーポレイテッド Ｌｒｒｋ２モジュレ−タ−としてのピラゾ−ルアミノピリミジン誘導体
KR102091895B1 (ko) 2012-05-03 2020-04-14 제넨테크, 인크. 파킨슨병의 치료에 사용하기 위한 lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체
MD20140130A2 (ro) 2012-06-29 2015-04-30 Pfizer Inc. 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
PE20161443A1 (es) 2014-01-29 2017-01-06 Glaxosmithkline Ip Dev Ltd Compuestos

Also Published As

Publication number Publication date
US20170022204A1 (en) 2017-01-26
AU2015210554A1 (en) 2016-07-07
WO2015113451A1 (en) 2015-08-06
US9815841B2 (en) 2017-11-14
JP2017504635A (ja) 2017-02-09
CN105980388A (zh) 2016-09-28
AU2018200271A1 (en) 2018-02-01
EP3099694B1 (en) 2019-01-16
CN105980388B (zh) 2018-01-16
RU2016134751A (ru) 2018-03-02
ES2717757T3 (es) 2019-06-25
EP3099694A4 (en) 2017-06-14
CA2937430A1 (en) 2015-08-06
EP3099694A1 (en) 2016-12-07

Similar Documents

Publication Publication Date Title
JP6474826B2 (ja) 化合物
JP6745824B2 (ja) 複素環化合物
JP5524171B2 (ja) キナーゼ阻害剤
JP2020526543A (ja) ロイシンリッチリピートキナーゼ２の阻害剤
TW200835481A (en) Imidazotriazines and imidazopyrimidines as kinase inhibitors
JP2020506966A (ja) 化合物
JP6698633B2 (ja) 複素環化合物
US11034696B2 (en) Compounds for inhibiting LRRK2 kinase activity
KR20160106623A (ko) 화합물
JP2020505399A (ja) 化合物
JP5266054B2 (ja) ピリミジン−４−イル−３，４−ジヒドロ−２ｈ−ピロロ［１，２ａ］ピラジン−１−オン化合物
BR112019015278A2 (pt) compostos
CN1842529A (zh) 用作蛋白激酶抑制剂的化合物和组合物
WO2019151269A1 (ja) 複素環化合物
JP2020505459A (ja) 化合物
EP4277893A1 (en) Indole derivatives as kinase inhibitors
CN120676947A (zh) 可用作mk2激酶降解剂的化合物和组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180918

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190130

R150 Certificate of patent or registration of utility model

Ref document number: 6474826

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees